[ad_1]
LONDON, November 26, 2020 / PRNewswire / – Haoma Medica today announced the completion of a first human study for NaQuinate, a naphthoquinone carboxylic acid, which is under development as a new orally administered drug for osteoporosis.
The first human study launched last year in healthy adults investigated single and multiple doses of NaQuinate. The main objective was to evaluate safety, tolerability and pharmacokinetics.
” We are delighted that the first human study has completed its latest dosage. There were no significant safety or tolerability concerns up to the highest doses tested, which underlines our expectation that NaQuinate is safe and well tolerated, ” said Dr. Cenk Oguz, Chief Medical Officer of Haoma Medica.
“Our preclinical research has revealed an exciting feature of NaQuinate in which it appears to have the ability to work in harmony with the body’s natural response to weight-bearing exercise to synergistically improve bone formation when and where required – now it would be a smart one.” drugs, “said Dr. Steve Deacon, CEO of Haoma Medica. “Together with the safety data from this first human study, this supports the potential that treatment with NaQuinate could provide a safe, novel and intelligent therapeutic approach to bone disorders such as osteoporosis and better maintain healthy skeletal aging.
About NaQuinate
Previous studies have shown that NaQuinate protects against the reduction in bone quality and quantity that occurs in response to ovariectomy in rodent models. In a mouse mechanical load model, a surrogate for exercise under load, NaQuinate synergistically improved the body’s normal response to load by forming bone, targeting relevant cortical bone regions. This synergistic interaction between NaQuinate and mechanical loading suggests the functional use of the bone mechanostat, a term that describes how mechanical loading affects bone structure, in the regulation of bone mass and architecture. NaQuinate is currently being evaluated using a curative model of osteoporosis versus a bisphosphonate and a loading model versus an anabolic; the results are expected early next year.
On osteoporosis
Osteoporosis is a silent disease that often does not present with any signs or symptoms until a fracture occurs. It therefore remains an underdiagnosed and untreated disease.
Osteoporosis causes bone loss and changes in bone quality and strength that occur through the normal aging process that leads to brittle bones. Brittle bones lead to fractures, which progress into a downward spiral of disability, loss of independence and increased mortality with a considerable social and economic burden. Fragility fractures are one of the main obstacles to healthy aging. Worldwide, there is a fragility fracture every 3 seconds.
According to the International Osteoporosis Foundation, around 200 million suffer from this disease worldwide. A combined lifetime risk of fractures is 40% and is equivalent to the risk of cardiovascular disease. In women over the age of 45, osteoporosis results in more time in hospitals than many other diseases such as breast cancer, heart attacks and diabetes.
About Haoma Medica
Haoma Medica is a clinical stage biotechnology company focused on developing therapies to maintain bone and vessel health.
For more information, visit www.haomamedica.com
Investor Relations Contact:
Name: Carmen Greco
e-mail: [email protected]
Logo – https://mma.prnewswire.com/media/1251548/Haoma_Medica_Logo.jpg
View original content: http: //www.prnewswire.com/news-releases/haoma-medica-completes-first-in-human-trial-for-naquinate-a-novel-treatment-in-development-for-osteoporosis- 301181026.html
View original content: http: //www.prnewswire.com/news-releases/haoma-medica-completes-first-in-human-trial-for-naquinate-a-novel-treatment-in-development-for-osteoporosis- 301181026.htmlSOURCE Haoma Medica
.
[ad_2]
Source link
